API Holdings (Pharmeasy) Unlisted Shares
PharmEasy investor cuts value of its stake drastically, implying new valuation of $456M
Tech Crunch
2 min read
PharmEasy Investor Slashes Stake Value, New Valuation Drops to $456M.
Expert Analysis:
New Valuation: PharmEasy is now valued at $456 million, based on Janus Henderson’s filing, which values its 12.9 million shares at $766,043.
Original Investment and Valuation Drop: Janus Henderson’s Global Research Fund originally spent $9.4 million to acquire the shares, with the current valuation down 92% from PharmEasy’s all-time high of $5.6 billion.
Fresh Capital and IPO Plans: Despite raising over $200 million in fresh capital earlier this year, the valuation remains low as PharmEasy prepares to file for an initial public offering next year.
Rights Issue and Capital Raised: In 2023, PharmEasy raised $417 million through a rights issue amidst a funding crunch, with $216 million secured by April 2024.
Backers and Market Position: PharmEasy, backed by Prosus, Temasek, TPG, and B Capital, operates one of India’s largest online pharmacies.
Thyrocare Acquisition: PharmEasy's current valuation is much lower than the $600 million it paid to acquire Thyrocare in 2021.
Financial Challenges: After deferring an $843 million IPO in 2021, PharmEasy struggled with debt, including a $300 million loan from Goldman Sachs, and difficulties raising new equity in a tough market.
PharmEasy’s valuation has dropped by 92%, reflecting ongoing financial struggles despite raising over $1 billion and securing fresh capital.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved